Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
It has been shown to produce significant weight loss when combined with healthy eating and exercise
This can stimulate angiogenesis at sites of tissue disruption in animal models ERK1/2 activation: Studies in preclinical settings have observed activation of extracellular signal-regulated kinases
Retatrutide is the only late-stage compound that provides significant glucagon receptor activation alongside GLP-1 and GIP agonism
REDEFINE 2 documented smaller mean weight loss (13.7%) in a diabetes population than REDEFINE 1 (22.7% on-treatment) in a population without diabetes a pattern consistent across the incretin-therapy literature (Lingvay et al., 2025
Pulmonary Fibroblast Models Pathological fibrosis, an endpoint of many chronic inflammatory diseases, involves the excessive deposition of ECM by activated fibroblasts
.webp)
